Almitrine

• CAT Number: I001775
• CAS Number: 27469-53-0
• Molecular Formula: C26H29F2N7
• Molecular Weight: 477.56
• Purity: ≥95%
• Synonyms: Vectarion; Almitrin; Almitrina; Almitrinum; Almitrine.;6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-N,N/’-diprop-2-enyl-1,3,5-triazine-2,4-diamine
• Target: agonist of peripheral chemoreceptor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• IUPAC Name: 6-[4-[bis(4-fluorophenyl)methyl]piperazin-1-yl]-2-N,4-N-bis(prop-2-enyl)-1,3,5-triazine-2,4-diamine
• InChI: InChI=1S/C26H29F2N7/c1-3-13-29-24-31-25(30-14-4-2)33-26(32-24)35-17-15-34(16-18-35)23(19-5-9-21(27)10-6-19)20-7-11-22(28)12-8-20/h3-12,23H,1-2,13-18H2,(H2,29,30,31,32,33)
• InChIKey: OBDOVFRMEYHSQB-UHFFFAOYSA-N
• SMILES: C=CCNC1=NC(=NC(=N1)N2CCN(CC2)C(C3=CC=C(C=C3)F)C4=CC=C(C=C4)F)NCC=C

Almitrine（Cat No.:I001775）is a respiratory stimulant that primarily acts by increasing ventilation in patients with chronic obstructive pulmonary disease (COPD) and other conditions characterized by hypoxemia. It works by stimulating peripheral chemoreceptors in the carotid bodies, which leads to enhanced respiratory drive and improved oxygenation. Almitrine has been used to improve arterial oxygen levels and help manage symptoms of respiratory failure. Although it can be effective in some patients, its use has declined due to side effects like peripheral vasoconstriction and the availability of alternative treatments. Ongoing research seeks to optimize its clinical applications.

Reference

1:Doppler study of the effects of inhaled nitric oxide and intravenous almitrine on regional pulmonary blood flows in patients with acute lung injury. Bouhemad B, Barbry T, Soummer A, Lu Q, Rouby JJ.Minerva Anestesiol. 2014 May;80(5):517-25. Epub 2013 Dec 4. PMID: 24299918 Free Article2:Almitrine fails to improve oxygenation during one-lung ventilation with sevoflurane anesthesia. Bermejo S, Gallart L, Silva-Costa-Gomes T, Vallès J, Aguiló R, Puig MM.J Cardiothorac Vasc Anesth. 2014 Aug;28(4):919-24. doi: 10.1053/j.jvca.2013.03.019. Epub 2013 Sep 7. PMID: 24016684 3:Almitrine-Raubasine combination for dementia. Yang W, Liu M, Teng J, Hao Z, Wu B, Wu T, Liu GJ.Cochrane Database Syst Rev. 2011 Mar 16;(3):CD008068. doi: 10.1002/14651858.CD008068.pub2. Review. PMID: 21412915 4:Stability-indicating methods for the determination of a mixture of almitrine and raubasine by derivative spectrophotometry. El-Sayed MA.Drug Test Anal. 2009 Jun;1(6):279-85. doi: 10.1002/dta.48. PMID: 20355207 5:[Combination of thiotropium bromide with almitrine and pulmonary rehabilitation in the treatment of patients with chronic obstructive pulmonary disease]. Titova ON, Ignat/’ev VA, Didur MD, Kameneva MIu, Sukhovskaia OA.Ter Arkh. 2008;80(3):28-33. Russian. PMID: 18441680 6:Nitric oxide and almitrine: the definitive answer for hypoxemia. Payen DM, Muret J.Curr Opin Anaesthesiol. 1999 Feb;12(1):37-42. PMID: 17013295 7:Low- vs high-dose almitrine combined with nitric oxide to prevent hypoxia during open-chest one-lung ventilation. Silva-Costa-Gomes T, Gallart L, Vallès J, Trillo L, Minguella J, Puig MM.Br J Anaesth. 2005 Sep;95(3):410-6. Epub 2005 Jul 15. PMID: 16024585 8:Assessment of the therapeutic activity of a combination of almitrine and raubasine on functional rehabilitation following ischaemic stroke. Li S, Long J, Ma Z, Xu Z, Li J, Zhang Z.Curr Med Res Opin. 2004 Mar;20(3):409-15. PMID: 15025850 9:Treatment of hypoxemia during one-lung ventilation using intravenous almitrine. Dalibon N, Moutafis M, Liu N, Law-Koune JD, Monsel S, Fischler M.Anesth Analg. 2004 Mar;98(3):590-4, table of contents. PMID: 14980903 10:Effects of almitrine bismesylate on arterial blood gases in patients with chronic obstructive pulmonary disease and moderate hypoxaemia: a multicentre, randomised, double-blind, placebo-controlled study. Górecka D, Sliwiński P, Pałasiewicz G, Pachocki R, Zieliński J; Almitrine Study Group..Respiration. 2003 May-Jun;70(3):275-83. PMID: 12915747